📝 What This Document Is 📰

This document is a Form 6-K press release (Exhibit 99.1) announcing that Nanobiotix presented new, highly technical preclinical data at the 2026 Annual Meeting of the American Association for Cancer Research (AACR). Essentially, the company is providing an early look at how its proprietary technology could improve the delivery of advanced cancer treatments.

The main takeaway is that Nanobiotix's platform, Nanoprimer, showed promising results in improving the delivery and safety of advanced therapies in a mouse model.

🔬 The Nanoprimer Technology Platform 🧬

Nanoprimer is at the core of Nanobiotix’s strategy. In simple terms, it is a nanotherapeutic platform designed to solve a major problem in modern medicine: how to get drugs into the right place without the liver trapping them first.

• Mechanism: The platform works by transiently modulating natural clearance pathways, particularly those in the liver. This allows therapeutic agents—which might otherwise be captured by the liver—to circulate longer and reach their intended target tissues, such as tumors.
• Purpose: The technology aims to increase drug bioavailability (how much drug actually gets into the bloodstream) or reduce unintended side effects, specifically related to liver toxicity.
• Versatility: Nanoprimer is not a single drug; it is a "therapeutic companion platform" designed to be used in combination with advanced therapies across multiple drug classes, including RNA and gene therapies.

🏢 What Nanobiotix Does 🔬

Nanobiotix is a late-stage clinical biotechnology company dedicated to developing nanotherapeutic approaches to revolutionize treatment outcomes for patients with cancer and other major diseases. The company's mission focuses on pushing past current scientific boundaries to expand possibilities for human life.

• History and Scale: Incorporated in 2003, Nanobiotix is headquartered in Paris, France. It has been listed on Euronext Paris since 2012 and the Nasdaq Global Select Market in New York City since December 2020.
• Patents: The company is the owner of more than 30 umbrella patents associated with three nanotechnology platforms: 1) oncology; 2) bioavailability and biodistribution (how well drugs move through the body); and 3) disorders of the central nervous system.
• Operational Scope: Nanobiotix is building its technology through a dual path: strategic external collaborations and developing its own internal, proprietary pipeline of Nanoprimer-enabled assets.

💡 The Preclinical Findings 🧪

The core finding comes from preclinical evaluations in a mouse model, testing Nanoprimer pre-treatment in conjunction with Lipid Nanoparticle-delivered recombinant DNA (LNP-DNA). This study directly addresses the major barriers faced by advanced drug deliveries.

• The Problem: Advanced therapies like LNP-DNA often face two issues: 1) rapid hepatic clearance via the Mononuclear Phagocyte System (MPS)—meaning the liver quickly filters them out; and 2) triggering transient acute inflammation through the cGAS/STING pathway.
• The Test: Researchers administered LNP-DNA vehicles designed for anti-tumor immunotherapy to mice, either with or without pre-treatment using Nanoprimer.
• Key Improvements with Nanoprimer:
  • Increased Bioavailability: Nanoprimer was shown to increase the circulating levels of LNP-DNA, improving the overall delivery of the therapy.
  • Reduced Toxicity: It reduced the amount of LNP-DNA taken up by the liver, leading to better hepatic tolerability.
  • Mitigated Inflammation: The technology helped reduce the activation of the cGAS-STING pathway, which is a marker of inflammatory response.

👉 Why it matters: These results suggest that Nanoprimer can act as a systemic "detour," allowing highly valuable, but otherwise poorly delivered, anti-cancer drugs to reach their target areas better and with fewer side effects.

🚀 Strategic Direction and Outlook 🎯

Nanobiotix is confirming that these promising preclinical results support the further evaluation of Nanoprimer. The CEO emphasized a clear and methodical approach to bringing this technology to market.

• CEO Commentary: Laurent Levy, Nanobiotix CEO and Chairman of the Executive Board, stated, “We continue our dual path approach to the development of our next-wave Nanoprimer platform in which we are both pursuing external collaborations with partners developing innovative therapeutic candidates that are challenged by liver accumulation, as well as our own proprietary internal pipeline.”
• Hypothesis Confirmation: He added, “We are encouraged by these preclinical results, generated in collaboration with Earli, which further support our hypothesis that the Nanoprimer may improve therapeutic efficacy while mitigating toxicity when sequenced prior to the administration of advanced therapeutics such as LNP-DNA and an additional layer of proof of concept.”

📅 Who to Contact and Key Dates 📞

This section provides crucial contact details for investors and media, ensuring readers know where to follow up on this exciting development.

• Investor Relations (US): Joanne Choi, VP, Investor Relations. Call: +1 (713) 609-3150. Email: [email protected].
• Investor Relations (EU): Ricky Bhajun, Director, Investor Relations. Call: +33 (0) 79 97 29 99. Email: [email protected].
• Media Relations (France): HARDY Caroline. Call: +33 06 70 33 49 50. Email: [email protected].
• Media Relations (Global): Becky Lauer. Call: +1 (646) 286-0057. Email: [email protected].

🧠 The Analogy 🌉

Imagine you are trying to send a priceless gift (your drug) across a bustling, dangerous city (the bloodstream) to a specific house (the tumor). Normally, the city's most visible bouncer, the liver (the MPS), intercepts and traps the gift almost instantly. Nanoprimer acts like a specialized, temporary side road or detour that guides the gift past the bouncer’s usual route, allowing it to travel further and arrive intact at the intended house, and perhaps even reducing the stress (toxicity) on the bouncer himself.

🧩 Final Takeaway 💡

Nanobiotix demonstrated that its Nanoprimer platform can significantly improve the delivery, bioavailability, and safety of advanced anti-cancer therapies by mitigating the liver’s natural trapping mechanism. This strengthens the company's position as a leader in drug delivery optimization for future pipeline development.